Australia’s ChemGenex High On Leukemia Drug After Trial Results
This article was originally published in PharmAsia News
Executive Summary
ChemGenex of Australia said the latest trial results of its omacetaxine drug to treat chronic myeloid leukemia are so promising it expects the medicine to be on the U.S. market by next March. The new results show an 85 percent remission rate for trial participants who are resistant to standard treatments, ChemGenex said. Analysts see the U.S. market for its drug worth $250 million in 2012 alone. CEO Greg Collier said that based on the positive results, the firm already is interviewing for a chief commercial officer to market the drug. (Click here for more
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.